Martin Edelman, MD

Articles by Martin Edelman, MD

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

ByDavid R. Gandara, MD,Martin Edelman, MD,Primo N. Lara, Jr, MD,Derick H. M. Lau, MD, PhD,Peter Roberts, MD,Bryan R. Leigh, MD

July 2nd 2000

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung

Latest Updated Articles

Uptake of Nononcology Gene Therapy Remains Slow in Hematology
Published: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
Published: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 Data
Published: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy
Published: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMD
Published: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision
Published: May 18th 2023 | Updated:

Martin Edelman, MD

Articles by Martin Edelman, MD

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

Latest Updated Articles

Trending on CGTlive®

Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation

Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025

Using Targeted Locus Amplification to Analyze Genetically Modified Cells